ABBV 8-K 2026-07-31
AbbVie Inc. (ABBV) 8-K dated 2026-07-31 — accession 0001551152-26-000023. This URL is the filing, not the ABBV hub.
AbbVie Inc. (ABBV) is a drug manufacturers - general company listed on US. It is led by Rob Michael.
ABBV to acquire platform ($10.9B)
Cached items: 2.02, 9.01. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.
Latest reported ABBV revenue for 2025-12-31 was $61.16B. Net income was $4.23B. Revenue was up 8.6% from 2024-12-31 to 2025-12-31. ABBV currently screens at market cap $334.34B.
Not investment advice. The ABBV SEC hub lists recent forms. The stock page is the research view.
- Diluted EPS
- $2.03
- Guidance
- Guidance Range from $13.91 - $14.11 to $13.87 - $14.07; Now Includes a $0.14 per Share Dilutive Impact Related to the Proposed A
- Deal
- $10.9B
Why it matters
- Guidance Range from $13.91 - $14.11 to $13.87 - $14.07; Now Includes a $0.14 per Share Dilutive Impact Related to the Proposed A
- Transaction value about $10.9B